NCT02425306 - Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 12, 2015

Primary Completion Date

August 18, 2017

Study Completion Date

January 8, 2018

Conditions

Melanoma

Interventions

BIOLOGICAL

6MHP

6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

DRUG

Montanide ISA-51

Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant

DRUG

polyICLC

polyICLC, local adjuvant

DRUG

Cyclophosphamide

Cyclophosphamide, systemic adjuvant

Trial Locations (1)

Cancer Center at the University of Virginia, Charlottesville